Impact of Early Treatment with Pimavanserin on Healthcare Resource Utilization Among Newly Diagnosed Patients with Parkinson’s Disease Psychosis: A Pre-Post Medicare Claims Database Analysis
Newly diagnosed PDP patients initiating pimavanserin within 6 months demonstrated significant reductions in 6-month post-index all-cause and psychiatric-related HCRU. Further analysis examining the association between time of pimavanserin initiation and the magnitude of benefits are warranted.
Authors
- Lambros Chrones (ORCID: https://orcid.org/0000-0001-7822-9364)
- Dilesh Doshi (ORCID: https://orcid.org/0009-0006-0970-2158)
- Daksha Gopal (ORCID: https://orcid.org/0000-0003-2710-980X)
- Nazia Rashid
- Krithika Rajagopalan
Institutions
- Acadia Pharmaceuticals (United States) (US)
- American Society for Neurochemistry (US)
Publication Details
- Journal
- Journal of health economics and outcomes research
- Published
- 2026-01-23
- DOI
- https://doi.org/10.36469/001c.154805
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- ACADIA Pharmaceuticals